SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull ($BULL) is trending due to a significant price drop, sparking intense debate among investors regarding potential insider selling after a lock-up period expired. The community is actively analyzing trading volume and support levels, with some viewing the dip as a buying opportunity, while others express concern about continued selling pressure. Amidst the volatility, there's speculation about a potential short squeeze and comparisons to similar situations with other trading platforms.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending amid discussions of a potential bubble in the quantum computing sector and scrutiny of its high valuation relative to revenue. Community chatter includes debate between bullish and bearish viewpoints, with some highlighting insider selling and concerns about future dilution, while others remain optimistic about the long-term potential of quantum computing. Technical analysis and pattern observations are also prominent in the conversation.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending as the community debates whether the stock is in a bubble, especially after a recent article cautioned about quantum stocks. Some traders point to insider selling and high valuation metrics to support a bearish outlook, while others remain bullish, citing the potential of quantum computing and ongoing momentum.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending as investors react to news of a significant deal with OpenAI, including OpenAI potentially acquiring a substantial stake in AMD. The community buzz centers on the implications of this partnership for AMD's position in the AI chip market, with some anticipating significant growth and others cautioning about overvaluation. Bullish sentiment is strong, with many seeing AMD as a key player in the future of AI.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

QUBT is trending amidst community discussion around a recent private placement and its potential impact, with debates focusing on dilution versus the company's increased financial strength. Some traders are pointing to technical indicators and anticipating a short squeeze, while others express concerns about the company's fundamentals and an ongoing SEC investigation; the stock's movement is also discussed in the context of the broader quantum computing sector.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum Inc. is trending amid fluctuating sentiments, with community members debating whether it's experiencing a classic panic sell-off or a bear trap. Some traders are suggesting taking profits, while others urge holding for a potential surge, emphasizing the company's long-term prospects in the quantum computing sector. The conversation includes discussion of a newly launched ETF that shorts QBTS.

Fitell Corp. engages in the business of selling gym and fitness equipment. It also offers turnkey solution for personal training studios and commercial gym chains. Its brands include Muscle Motion, Rapid Motion, and FleetX. The company was founded in 2007 and is headquartered in Sydney, Australia.

Fitell Corp - Ordinary Shares - Class A

Fitell Corp

FTEL is trending due to high volume and community discussion around its low float and potential for a significant price increase. The company's recent investment in a Solana treasury and Nasdaq extension are being viewed as positive catalysts. Community members are actively discussing potential price targets and the possibility of a short squeeze.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.

Recursion Pharmaceuticals Inc - Ordinary Shares - Class A

Recursion Pharmaceuticals Inc

RXRX is trending due to community discussion around its potential for a short squeeze, driven by high short interest and unusual options activity. Some investors are optimistic about the company's AI-driven drug discovery platform, particularly its use case in healthcare, and potential catalysts. Others remain cautious, pointing to insider selling and cash burn as concerns.

American Rebel Holdings, Inc. engages in the design and marketing of branded safes, and personal security and self-defense products. It also designs and manufactures branded apparel and accessories. The company was founded on December 15, 2014 and is headquartered in Brentwood, TN.

American Rebel Holdings Inc

American Rebel Holdings is trending due to an announced 1-for-20 reverse stock split with a unique "round lot protection" provision guaranteeing those holding at least 100 shares will maintain that amount post-split, sparking community debate and speculative trading strategies. Traders are actively discussing the potential for a short squeeze and the stock's volatile history, while also evaluating the implications of insider selling and a recent resolution of debt with Bank of America. The community is weighing the risks and potential rewards of this situation.

AlphaTON Capital Corp. is a biotechnology company, which engages in the research and development of immuno-oncology therapies for patients with cancer. Its portfolio includes first-in-class invariant natural killer T cell (iNKT) small molecule engagers and best-in-class adenosine antagonists. The company was founded by Gregory H. Bailey and James Mellon in 1973 and is headquartered in Road Town, British Virgin Islands.

AlphaTON Capital Corp.

AlphaTON Capital Corp. is trending as community members discuss the potential impact of the company's focus on building a TON token treasury and its integration with the Telegram ecosystem. Some traders are drawing comparisons to other recent low-float runners and anticipating a significant price movement. However, other investors caution about potential dilution and the company's shift in focus from biotech to crypto.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Spruce Biosciences (SPRB) surged to a 19-month high of $240 in Tuesday morning trading, prompting two trading halts due to extreme volatility.Trading was halted at 9:32 a.m. ET and again at 9:48 a.m. ET, according to data from Nasdaq Trader, citing a ‘Volatility Trading Pause’.<a href="http://stocktwits.com/symbol/SPRB">SPRB’s stock</a> was up 74%, trading around $229 at the time of writing. It ranked among the top trending tickers on Stocktwits, with retail sentiment climbing higher within ‘extremely bullish’ territory amid ‘extremely high’ chatter – recording the highest levels of retail activity seen this year. Data also showed that the number of retail traders monitoring SPRB shares jumped 76% over the past day.<figure class="image"><img style="aspect-ratio:1259/133;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_07_101031_png_dc3a1a3a6c.webp" alt="Screenshot 2025-10-07 101031.png" width="1259" height="133"><figcaption>SPRB retail sentiment and message volume on October 7 as of 10:00 a.m. ET | Source: Stocktwits</figcaption></figure>The rally follows Spruce Biosciences’ shares jumping 1,378% to close at $130.4 on Monday after the U.S. Food and Drug Administration (FDA)&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/spruce-biosciences-stock-more-than-quadruples-after-breakthrough-therapy-designation-to-therapy-for-rare-fatal-genetic-disease/ch6R7WfR3gl">granted</a> Breakthrough Therapy Designation to tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB).Martin Shkreli also&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/spruce-biosciences-stock-nearly-doubles-premarket-pharma-bro-martin-shkreli-sees-280-upside/ch6PEVhR3Wj">disclosed</a> his long position in Spruce and expressed a bullish outlook. In a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/MartinShkreli/status/1975241784369262649">post</a> on X, Shkreli said he believes the treatment “will be approved” and become “the new standard of care,” predicting that Spruce’s stock could rise to $500. Shkreli, a former hedge fund manager and pharmaceutical executive who&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.justice.gov/usao-edny/pr/martin-shkreli-sentenced-seven-years-imprisonment-multi-million-dollar-fraud-scheme">served time</a> for securities fraud, did not provide a timeline for the forecast.MPS IIIB is a rare, inherited lysosomal storage disease that causes a gradual decline in motor skills and cognition, as well as hyperactivity with aggressive behavior. CEO Javier Szwarcberg said on Monday that the company is preparing to submit an application for approval of the therapy in MPS IIIB in the first quarter of 2026.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bnb-token-surges-to-record-high-overtakes-xrp-as-third-largest-cryptocurrency/ch6PaXTR3Wy">BNB Token Surges To Record High, Overtakes XRP As Third-Largest Cryptocurrency</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of abstract numbers amid rising stock market prices. (Photo by SEAN GLADWELL/Getty Images)

SPRB Stock Hits 19-Month High Amid Trading Halts

The rally follows Spruce Biosciences’ shares jumping 1,378% to close at $130.4 on Monday.

Equity

The rally follows Spruce Biosciences’ shares jumping 1,378% to close at $130.4 on Monday.


Spruce Biosciences' stock&nbsp;leaped over 90% in early premarket trading on Tuesday, topping the Stocktwits trending list,&nbsp;hours after investor Martin Shkreli disclosed his long position on the stock and discussed his optimistic outlook.That's after SPRB stock gained a staggering 1,378% to $130.4 in Monday's session, following the company's announcement that it&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/spruce-biosciences-stock-more-than-quadruples-after-breakthrough-therapy-designation-to-therapy-for-rare-fatal-genetic-disease/ch6R7WfR3gl">received</a> the FDA's 'Breakthrough Therapy Designation' for its new therapy for a rare neurological disease.Spruce's tralesinidase alfa enzyme replacement therapy (TA-ERT) is designed to treat Sanfilippo syndrome type B (MPS IIIB), a rare, inherited lysosomal storage disease that causes a gradual decline in motor skills and cognition, as well as hyperactivity with aggressive behavior.Shkreli said in an&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/MartinShkreli/status/1975241784369262649">X post</a> early Tuesday he believes the said treatment "will be approved" and become "the new standard of care," forecasting that it would push Spruce's stock to $500.&nbsp;Shkreli, a former hedge fund manager and pharmaceutical executive who has served time in jail for securities fraud, did not provide a timeline."I was working on a presentation when the news was scooped. but this drug restores the abnormally high levels of heparan sulfate to normal. without this drug, patients will die at 18. with normal ranges of HS, they may live a normal life," he said in a follow-up post.CEO Javier Szwarcberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251006024469/en/Spruce-Biosciences-Receives-U.S.-FDA-Breakthrough-Therapy-Designation-for-Tralesinidase-Alfa-Enzyme-Replacement-Therapy-TA-ERT-in-Sanfilippo-Syndrome-Type-B-MPS-IIIB">said</a> on Monday that the company is preparing to submit an application for approval of the therapy in MPS IIIB in the first quarter of 2026. According to Spruce, Sanfilippo Syndrome Type B affects one in 200,000 people in the U.S.FDA's 'Breakthrough Therapy Designation' expedites the development and regulatory review of promising therapies for serious or life-threatening conditions, with intensive FDA guidance.Notably, Shkreli also recently&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pharma-bro-martin-shkreli-bets-against-opendoor-but-retail-traders-call-it-an-obvious-long-backed-by-eric-jackson/chw0M0bRdsE">revealed a short position</a> in Opendoor Technologies' shares, a widely watched meme stock.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Spruce Biosciences Stock Nearly Doubles Premarket: 'Pharma Bro' Martin Shkreli Sees 280% Upside

SPRB stock surged by over 1,300% on Monday after the biotech firm received the FDA's 'Breakthrough Therapy Designation' for its new therapy for a rare neurological disease.

Spruce Biosciences (SPRB) on Monday said that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B.Sanfilippo syndrome type B (MPS IIIB) is a rare, inherited lysosomal storage disease caused by a deficiency in the enzyme alpha-N-acetylglucosaminidase, leading to the accumulation of heparan sulfate in cells, particularly neurons. It causes progressive neurological symptoms like cognitive and developmental impairment, hyperactivity with aggressive and destructive behavior, delayed speech, hearing loss, and motor skill deficits.Tralesinidase Alfa Enzyme Replacement Therapy is intended as an enzyme replacement therapy for the treatment of patients with MPS IIIB. The Breakthrough Therapy Designation is designed to expedite the development and regulatory review of promising therapies for serious or life-threatening conditions. It enables intensive FDA guidance and eligibility for rolling submission and priority review.Shares of SPRB traded 314% higher at the time of writing on Monday. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SPRB">SPRB stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours while message volume stayed at ‘extremely high’ levels.CEO Javier Szwarcberg <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251006024469/en/Spruce-Biosciences-Receives-U.S.-FDA-Breakthrough-Therapy-Designation-for-Tralesinidase-Alfa-Enzyme-Replacement-Therapy-TA-ERT-in-Sanfilippo-Syndrome-Type-B-MPS-IIIB">said</a> that the company is preparing to submit an application for approval of the therapy in MPS IIIB in the first quarter of 2026. According to Spruce, Sanfilippo Syndrome Type B affects one in 200,000 people in the U.S.Currently, there are no FDA-approved therapies for the disease, which drastically brings down the life expectancy of individuals to 15-19 years of age.SPRB stock rose over 200% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-listed-nyxoah-shares-soar-on-first-genio-system-implants-in-patients-with-sleep-disorder/ch6R4LYR3g1">US-Listed Nyxoah Shares Soar On First Genio System Implants In Patients With Sleep Disorder</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did Spruce Biosciences Stock Quadruple Today?

The FDA’s Breakthrough Therapy Designation is designed to expedite the development and regulatory review of promising therapies for serious or life-threatening conditions.

Puma Biotech (PBYI) Surpasses Q2 Earnings and Revenue Estimates

Puma Biotech (PBYI) delivered earnings and revenue surprises of +36.36% and +4.42%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Curis (CRIS) Reports Q2 Loss, Beats Revenue Estimates

Curis (CRIS) delivered earnings and revenue surprises of +65.83% and +14.54%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Illumina (ILMN) Q2 Earnings and Revenues Surpass Estimates

Illumina (ILMN) delivered earnings and revenue surprises of +16.67% and +1.11%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Spruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAH

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological and endocrine disorders with significant...

Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant...

Spruce Biosciences to Participate in the Guggenheim Securities Healthcare Innovation Conference

Spruce Biosciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Spruce Biosciences, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.

Spruce Biosciences Inc

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

SPRB
Spruce Biosciences Inc

Feed

News

Sentiment

Fundamentals

Info

Latest SPRB News

SPRB Spruce Biosciences Inc